Loading
Galectins and Cancer Biology / Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Journal article
Diagnostyka Laboratoryjna · June 29, 2026
The material analysed did not support any firm read.
This narrative review of 23 articles concludes that galectin-3, although established as a cardiac biomarker in adults, shows inconclusive utility in pediatric arrhythmia diagnosis and risk stratification. The biomarker reflects structural myocardial changes more strongly than electrical disturbances, and current evidence does not support routine clinical use in children pending further multicenter study.
Narrative review. Published studies examining galectin-3 in pediatric cardiology and arrhythmia diagnosis.
Gal-3 is an effective marker of fibrosis and inflammation in kidney diseases and cystic fibrosis Gal-3 significance in diagnosis of pediatric arrhythmias remains inconclusive Gal-3 reflects structural changes in myocardium more strongly than electrical disturbances
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should not rely on Gal-3 for routine diagnosis or risk stratification of arrhythmias in the pediatric population. Further multicenter prospective studies are needed before clinical recommendations can be made.
This is a narrative review concluding that Gal-3's role in pediatric arrhythmia diagnosis remains inconclusive, with inconsistent data and small study groups preventing clinical recommendation.
As stated by the source record.
Clinicians should not rely on Gal-3 for routine diagnosis or risk stratification of arrhythmias in the pediatric population. Further multicenter prospective studies are needed before clinical recommendations can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Galectin-3 (Gal-3) is a recognized cardiac biomarker with establishedprognostic value in adults; however, its role in the pediatric population stillrequires verification. This study aimed to evaluate the utility of Gal-3 in pediatriccardiology, with a particular focus on the diagnosis and risk stratification ofventricular, supraventricular, and idiopathic heart rhythm disorders. Based ona review of the PubMed, Web of Science, and Embase databases, twenty-three articles meeting the substantive criteria were included in the analysis. It was demonstrated that Gal-3 is an effective marker of fibrosis and inflammation (e.g., in kidney diseases or cystic fibrosis), yet its significance inthe diagnosis of pediatric arrhythmias remains inconclusive. This biomarker reflects structural changes in themyocardium more strongly than electrical disturbances themselves. The primary limitations of using Gal-3 inpediatrics include low organ specificity, the influence of metabolic factors (e.g., obesity and diabetes), and smallstudy groups in available prospective trials. Due to inconsistent data, Gal-3 is currently not recommended forroutine clinical practice in children. Gal-3 remains an insufficiently studied biomarker of arrhythmia in this agegroup, indicating a need for further multicenter studies to establish its actual diagnostic value.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.